ClinicalTrials.gg
WithdrawnNCT07566585Updated Sep 10, 2026

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

A Phase 1 interventional study of SOC+ BSB-2002 and SOC+BSB-2002 in AML - Acute Myeloid Leukemia, AML With Mutated NPM1 and AML, Adult Recurrent, sponsored by BlueSphere Bio, Inc. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by BlueSphere Bio, Inc · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Company Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States — 309 open to participants now, 463 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
1,857th of 1,908
0 · median 35
Started
2026
with 72 others
Phase 1
772 of 2,138
127 open now
Registered
2,105th of 2,138
by date

Among the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 1,857th largest by enrollment of the 1,908 interventional ones that give a count, is one of 73 that started in 2026, is one of 772 in phase 1, and was the 2,105th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 814 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

309 of the 2,138 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

304 more — sign in →

All 309 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 619 Leukemia, Myeloid, Acute studies recruiting now, 360 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,138 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.

Read the detailed description

This is a Phase I, multicenter, open-label, non-randomized study to characterize the safety and clinical activity of BSB-2002, a genetically modified autologous T cell product incorporating an HLA-A*02:01-restricted mutant NPM1-directed T cell receptor (TCR), administered to patients with relapsed or refractory acute myeloid leukemia (AML). Enrolled patients must be HLA-A*02:01+ and positive for the NPM1 mutation which produces the alternative amino acid sequence CLAVEEVSL (Type A, D, G or H).

The study is an adaptive dose escalation design with up to 3 cohorts to evaluate single doses of BSB-2002, employing the 3+3 design.

03

Conditions studied

  • AML - Acute Myeloid Leukemia
  • AML With Mutated NPM1
  • AML, Adult Recurrent

Keywords

  • TCR
  • T-cell therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients, ages 18 years or older,
  2. AML diagnosed per ELN criteria1 which has been treated with at least two ,

    1. which is (after previously complete remission, CR, CRh or CRi), or
    2. refractory (failed to achieve complete remission) to the last treatment*, *Primary refractory patients should have received at least two cycles of induction treatment
  3. Patients who are MRD positive by NGS for NPM1 after being MRD negative following the last treatment
  4. HLA-A*02:01,
  5. Positive for NPM1 mutation type A, D, G or H (see Appendix 3)2
  6. Adequate venous access for apheresis or agree to use of a central line for apheresis collection,
  7. Willing and able to provide and adhere to all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Leukemic blast count of >20,000/μl. If the blast count can be maintained below the threshold with hydroxyurea, the patient would be eligible.
  2. Patients with extramedullary only AML.
  3. Patients that are candidates for hematopoietic stem cell transplant.
  4. Patients that are eligible to receive an approved targeted therapy.
  5. Treatment with other agents within 5 half-lives of the planned dosing of BSB-2002 (day 1).
  6. Subject has had hematopoietic stem cell transplant () and has any of the following:

    1. Is within 3 months of transplant;
    2. Has requiring systemic treatment;
    3. Has ≥ Grade 2 persistent non-hematological toxicity related to the transplant.
  7. Other that requires treatment.
  8. Uncontrolled bacterial, viral, or fungal infections at time of enrollment.
  9. Active or C infection.
  10. Seropositive for -1 or -2.
  11. CNS involvement to intrathecal chemotherapy and/or standard cranial- spinal radiation.
  12. Subject has congestive heart failure class 3 or 4, or subject with a history of congestive heart failure NYHA class 3 or 4 in the past, unless an echocardiogram performed within 3 months prior to study entry results in a that is ≥ 45%.
  13. Renal insufficiency, with estimated of \< 40 ml/min/1.73m2 by the Cockcroft-Gault equation with adjustment if the weight is ≥ 125% of ideal body weight OR inadequate renal function defined by serum creatinine > 1.6 mg/dL
  14. Total > 2x (unless attributed to Gilbert's Syndrome).
  15. or ALT > 3x upper limit of normal.
  16. Pregnant or lactating women.
  17. (ECOG) performance status >2.
  18. Ongoing treatment with chronic (e.g., cyclosporine or systemic at any dose)
  19. Women of (WOCBP) and men who are fertile and are unwilling to use an effective method or abstinence for 12 months. Effective forms of birth control are listed in the Contraception section.
  20. Any condition, in the judgement of the Investigator, that would interfere with study participation, pose a significant risk to the patient, or interfere with study data interpretation.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Dose Escalation Cohorts

    AML HLA-A\*02:01 and Positive for NPM1 mutation type A, D, G or H patients with an identified will be dosed in dose escalation cohorts

    Drug: SOC+BSB-2002

  • Experimental
    Expansion Cohort

    Once the maximum tolerated dose (MTD) or promising dose is reached additional AML HLA-A\*02:01 and Positive for NPM1 mutation type A, D, G or H patients will be enrolled in the expansion cohort.

    Drug: SOC+ BSB-2002

Interventions

  • DrugSOC+ BSB-2002

    Patients will receive BSB-2002 as a single IV infusion at day 1 following the lymphodepletion regime.

  • DrugSOC+BSB-2002

    Patients will receive BSB-2002 as a single IV infusion at day 1 following the lymphodepletion regime.

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicity, adverse events (AEs) and serious AEs (SAEs)

    Incidence of dose-limiting toxicity, frequency and severity of adverse events (AEs) and serious AEs (SAEs)

    Time frame: 365 days

Secondary outcomes

  1. Number of Patients with Relapse

    Presence of malignant cells in marrow (\>5%), peripheral blood (\>1%), or extramedullary sites by histopathology after achievement of CR, CRh or CRi any time after study treatment.

    Time frame: 365 days

  2. Cellular kinetics of BSB-2002 in peripheral blood

    Quantitation of BSB-2002 (copies per μL of genomic DNA)

    Time frame: 365 days

  3. Overall survival

    Defined as the time from treatment to death due to any cause

    Time frame: Through 365 days

Other outcomes

  1. Malignant Cell presence detected by Molecular MRD Methods

    Presence of malignant cells in the marrow, peripheral blood, or extramedullary sites detectable only by molecular methods

    Time frame: 365 days

  2. Cellular kinetics of serum cytokines and biomarkers

    Evaluation of inflammatory cytokines and other potential biomarkers

    Time frame: 365 days

07

Study locations

1 site
  • Washington University at St Louis
    St Louis, Missouri 63110, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Sep 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 5, 2026
StartActual
Apr 21, 2026
Primary completionActual
Sep 8, 2026
CompletionActual
Sep 8, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07566585
Lead sponsor
BlueSphere Bio, Inc
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Apr 21, 2026
Primary completion
Sep 8, 2026
Completion
Sep 8, 2026
Last update
Sep 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion